Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.36 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 2/20 | 0.33 |
| ▸ | FNTB | P49356 | 2/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18476660 | 0.84 | FOLH1 (0.43) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL3098909 | 0.82 | TGFBR1 (0.44) | FOLH1NAALAD2 | |
| SCHEMBL20358061 | 0.81 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18476619 | 0.81 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL20358105 | 0.81 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL25487492 | 0.81 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL20358162 | 0.81 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL20358106 | 0.81 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL20358164 | 0.81 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL25760029 | 0.80 | FOLH1 (0.39) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11110104-B2 | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-10954257-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | FOLH1 1528/4885NAALAD2 319/4885RIMKLA 16/4885 |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | FOLH1 403/4885NAALAD2 539/4885RIMKLA 180/4885 |
| US-10954257-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | FOLH1 403/4885NAALAD2 539/4885RIMKLA 180/4885 |
| US-11110104-B2 | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | GLUL, GLS2, SLC1A2 | FOLH1 1528/4885NAALAD2 319/4885RIMKLA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.